ReviewJournal of the American Chemical Society2025
Convergent Evolution: Self-Assembly of Small Molecule, Polymeric, and Inorganic Contrast Agents toward Advanced MRI.
Review in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Composition-tunable polycarboxylic acid-stabilized ultrasmall amorphous paramagnetic nanoclusters as multifunctional MRI contrast agents.Materials today. Bio · 2026Article
- Metal-Organic Framework as Contrast Agents for Magnetic Resonance Imaging.Pharmaceutics · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnetic resonance imaging (MRI) is a non-invasive technique providing detailed anatomical, physiological, and molecular information. Contrast agents (CAs), such as gadolinium-based chelates, enhance differentiation between normal and abnormal tissues, highlight blood vessels, and detect tumors, inflammation, or other conditions, to aid clinical diagnostics. Although small-molecule chelate-based CAs have been used clinically for several years, extensive research efforts have been directed toward enhancing CA properties, ranging from boosting their contrast-to-noise ratio to developing responsive agents, through careful design. This perspective examines the convergent (not chronological) evolution of different classes of CAs: small-molecule complexes, polymeric chelates, and inorganic nanoparticles. We outline how research across these types of CAs has led to self-assembled species showcasing superior MRI performance compared to traditional agents. Despite different mechanisms driving the two main MRI CA classes (positive, T
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.